- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Novagali Pharma IND cleared for phase III study of cationic emulsion of latanoprost
Novagali Pharma announced that the company's investigational new drug application to conduct a phase III clinical trial of Nova21027 (Catioprost), a cationic emulsion of latanoprost for the treatment of glaucoma, has been granted by the FDA.
Fort Lauderdale, FL-Novagali Pharma announced that the company's investigational new drug application to conduct a phase III clinical trial of Nova21027 (Catioprost), a cationic emulsion of latanoprost for the treatment of glaucoma, has been granted by the FDA.
The topical ocular proprietary benzalkonium chloride (BAK)-free formulation of latanoprost presents a safer profile than BAK-containing marketed products for glaucoma, according to the company. The trial will aim to evaluate the safety and the efficacy of the product.
“With this fourth pharmaceutical product entering in clinical development, Novagali completes its late-stage product pipeline,” said Jerome Martinez, president and chief executive officer of Novagali Pharma. “We expect [the drug] to bring significant safety and comfort improvement for glaucoma patients, especially for those suffering from ocular surface diseases.”
